一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Adagrasib；Pembrolizumab；Carboplatin；Pemetrexed；Placebo；Cisplatin，当前状态为招募中。登记地点显示中国蚌埠、合肥、北京、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Adagrasib；Pembrolizumab；Carboplatin；Pemetrexed；Placebo；Cisplatin · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Afflilated Hospital of Bengbu Medical College · 蚌埠
- Anhui Provincial Hospital · 合肥
- Beijing Cancer hospital · 北京
- Beijing Peking Union Medical College Hospital · 北京
- Beijing Chest Hospital,Capital Medical University · 北京
- Chongqing University Cancer Hospital · 重庆
- Fujian Medical University Union Hospital · 福州
- The First Affiliated hospital of Xiamen University · 厦门
- The First Affiliated Hospital, Sun Yat-sen University · 广州
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Cancer Hospital of Shantou University Medical College · 汕头
- Cancer Hospital Chinese Academy of Medical Sciences. Shenzhen Center · 深圳
- ShenZhen People's Hospital · 深圳
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Fourth Hospital of Hebei Medical University · 石家庄
- Harbin Medical University Cancer Hospital · 哈尔滨
- Nanyang City Center Hospital · 南阳
- The First Affiliated Hospital of Xinxiang Medical University · 新乡
- Tongji Hospital Tongji Medical,Science & Technology · 武汉
- Hunan Cancer Hospital · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School · 南京
- The First Affiliated Hospital of Soochow University · 苏州
- Northern Jiangsu People's Hospital · 扬州
- The Second Affiliated Hospital of Nanchang University · 南昌
- The First Hospital of Jilin University · 长春
- The First Hospital of China Medical University · 沈阳
- Shengjing Hospital of China Medical University · 沈阳
- Liaoning Cancer Hospital · 沈阳
- Shandong Cancer Hospital · 济南
- LinYi Cancer Hospital · 临沂
- Shanghai Chest Hospital · 上海
- Local Institution - 0381 · 上海
- Shanghai East Hospital · 上海
- Shanxi Cancer Hospital · 太原
- Sichuan Cancer hospital · 成都
- West China Hospital, Sichuan University · 成都
- Tianjin Medical University General Hospital · 天津
- The first Affiliated Hospital, Zhejiang University School of Medicine · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Taizhou Hospital of Zhejiang Province · 台州
公开的入选条件
- * Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA).
- * Locally advanced or metastatic disease.
- * Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion.
- * No prior systemic anti-cancer therapy given for advanced or metastatic disease.
- * Not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection).
- * Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter.
- * Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay, Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06875310；登记信息更新于 2026-09-22。